Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking … Read more
Q32 Bio Inc (QTTB) - Total Liabilities
Latest total liabilities as of September 2025: $76.23 Million USD
Based on the latest financial reports, Q32 Bio Inc (QTTB) has total liabilities worth $76.23 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Q32 Bio Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Q32 Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Q32 Bio Inc Competitors by Total Liabilities
The table below lists competitors of Q32 Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zuari Agro Chemicals Limited
NSE:ZUARI
|
India | ₹15.46 Billion |
|
Novacyt S.A
PINK:NVYTF
|
USA | $25.73 Million |
|
Metal Sky Star Acquisition Corporation Ordinary shares
NASDAQ:MSSA
|
USA | $7.85 Million |
|
Healthcare Integrated Technologies Inc
PINK:HITC
|
USA | $849.40K |
|
HeXun Biosciences Co., Ltd.
TWO:6986
|
Taiwan | NT$89.01 Million |
|
Articore Group Ltd
AU:ATG
|
Australia | AU$63.56 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Q32 Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Q32 Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Q32 Bio Inc (2016–2024)
The table below shows the annual total liabilities of Q32 Bio Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $86.66 Million | -62.32% |
| 2023-12-31 | $229.98 Million | +19.48% |
| 2022-12-31 | $192.49 Million | +357.54% |
| 2021-12-31 | $42.07 Million | -37.90% |
| 2020-12-31 | $67.74 Million | +30.12% |
| 2019-12-31 | $52.06 Million | -17.02% |
| 2018-12-31 | $62.74 Million | +59.96% |
| 2017-12-31 | $39.22 Million | +483.75% |
| 2016-12-31 | $6.72 Million | -- |